In August 2015, the U.S. Food and Drug Administration approved the drug fibanserin, sold by Sprout Pharmaceuticals under the brand name Addyi, for use in treating premenopausal women with a low sexual desire, called hypoactive sexual desire disorder, or HSDD.…… Click here to read full article ›